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ABSTRACT
Using CRISPR/Cas9, it is possible to target virtu-
ally any gene in any organism. A major limitation to
its application in gene therapy is the size of Cas9
(>4 kb), impeding its efficient delivery via recombi-
nant adeno-associated virus (rAAV). Therefore, we
developed a split–Cas9 system, bypassing the pack-
aging limit using split-inteins. Each Cas9 half was
fused to the corresponding split-intein moiety and,
only upon co-expression, the intein-mediated trans-
splicing occurs and the full Cas9 protein is recon-
stituted. We demonstrated that the nuclease activ-
ity of our split-intein system is comparable to wild-
type Cas9, shown by a genome-integrated surro-
gate reporter and by targeting three different en-
dogenous genes. An analogously designed split-
Cas9D10A nickase version showed similar activity
as Cas9D10A. Moreover, we showed that the dou-
ble nick strategy increased the homologous directed
recombination (HDR). In addition, we explored the
possibility of delivering the repair template accom-
modated on the same dual-plasmid system, by tran-
sient transfection, showing an efficient HDR. Most
importantly, we revealed for the first time that intein-
mediated split–Cas9 can be packaged, delivered and
its nuclease activity reconstituted efficiently, in cells
via rAAV.
INTRODUCTION
The discovery of the bacterial clustered regularly in-
terspaced short palindromic repeats/CRISPR associated
(CRISPR)/Cas) system is a major breakthrough in genetic
engineering. Through its simplicity, it has made genome
modification accessible to the wide scientific community.
Cas9 is used as a generic nuclease, and a guide RNA
(gRNA) confers sequence specificity on Cas9 by carrying
an identical complementary sequence to a genomic region
of interest (1). Nevertheless, the use of CRISPR/Cas9 as an
advanced method for gene therapy has its limitations.
One of the challenges is to find an optimal delivery sys-
tem that could carry all CRISPR/Cas9 components to the
desired organ or cell population for genetic manipulation.
As a first attempt, plasmids coding for Streptococcus pyo-
genes Cas9 (SpCas9), gRNA and a donor oligonucleotide
were administered directly into the tail-vein via hydrody-
namic injection. In this proof of principle, the recovery from
the pathogenic phenotype of hereditary tyrosinemia, caused
by a mutation in the Fah gene, was shown in mouse (2).
Due to the low efficiency of gene correction and the method
used, its translation to broader use in gene therapy would be
limited to some disorders. In another attempt, adenovirus
was used as the delivery system to efficiently introduce a
loss-of-function mutation into the proprotein convertase
subtilisin/kexin type 9 (Pcsk9) gene. This strategy would be
expected to lead to decreased levels of low-density lipopro-
tein cholesterol and thus a reduced risk of cardiovascular
diseases (3). However, the implementation of adenovirus
in gene therapy can lead to a strong immune response, re-
stricting its use to acute treatments (4). The current stan-
dard delivery system used in humans is the recombinant
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adeno-associated virus (rAAV), due to their high infection
efficiency and very low immune response (5). Nonetheless,
their packaging capacity is confined to amaximumof∼4.7–
5 kb (6,7). The human optimized SpCas9 coding sequence
comprises over 4.2 kb, and, in combination with its neces-
sary promotor sequence and gRNA,would reach a size over
5 kb, complicating the efficient production of rAAV for car-
rying the complete CRISPR/Cas9 system.
Various strategies to diminish SpCas9 size were fol-
lowed: a) by deleting the non-essential REC2 lobe, result-
ing in a 133 amino acids (aa) smaller SpCas9. Albeit, the
SpCas9D175–307 retained <50% activity of the full-length
version (8); b) using smaller orthogonal SpCas9, e.g. from
Streptococcus thermophiles, from Neisseria meningitides or
from Staphylococcus aureus (9–12). However, their more
complex PAM requirements make it more difficult to find a
suitable target sequence. Moreover, recent reports indicate
an inverse correlation between the size of Cas9 orthologues
and the complexity of the PAM sequence. This hampers the
search for smaller SpCas9 orthologues with simple PAM re-
quirements (9,10).
Recently, the structure of Cas9 has been deciphered in its
apo-form and its RNA/DNA bound holo-form. This re-
vealed the bi-lobed shaped structure of Cas9 that undergoes
a large conformational re-arrangement upon binding the
gRNA/DNA (8,13). The two lobes consist of a recognition
lobe (REC) and a nuclease lobe (NUC). In between, there
is a positively charged groove where the negatively charged
nucleic acids of the holo-form reside. Structural studies ren-
der the rational engineering of Cas9 possible, either to equip
it with new functionalities or to change its characteristics.
Analogous to the development of split-CreERT2 recom-
binase (14) and split-TALENs (15), taking advantage of the
intein-extein system, it is of interest to have a precisely con-
trollable split-Cas9, to permit the spatiotemporal control of
SpCas9 activity. Post-translational regulation (e.g. by con-
trolling the dimerization of an artificial split-enzyme) oc-
curs within milliseconds or seconds, thus making it a pre-
cise spatiotemporally adjustable tool (16). We took advan-
tage of SpCas9 structural knowledge and designed and cre-
ated a split-intein mediated split–Cas9 trans-splicing sys-
tem. This system allows the coding sequence of Cas9 to be
distributed on a dual-vector system and reconstituted post-
translationally.
We demonstrated the split-intein split–Cas9 functionality
first by plasmid transfection and second by administration
of rAAV in vitro. We also showed that SpCas9D10A nick-
ase can be split as well, reconstituting its nickase activity.
In addition, we revealed that the repair template can be de-
livered efficiently when included in the dual-plasmid system
already encoding the CRISPR/Cas9 elements.
MATERIALS AND METHODS
Cell Culture
The Neuro-2a cell line (ACC 148, DSMZ, Germany) was
grown in complete Dulbecco’s modified Eagle’s medium
(Gibco-BRL, Rockville, MD, USA) at 37◦C and 5% CO2.
To generate the stable surrogate reporter cell line, the same
procedure published by Ortiz et al. (17) for M5/N9 cells
was used with the following modifications: cells were co-
electroporated with the linearized surrogate construct and
the linearized PGK-HygR-pA for the subsequent selection
against Hygromycin. After 2 weeks under selection, resis-
tant colonies were isolated and amplified. A battery of am-
plified clones was co-electroporated with Cas9, crTLR#1
and a donor DNA carrying the complete Venus sequence
plus 0.4 and 1.5 kb as 5′ and 3′ homology arms respectively.
Forty eight hours post-transfection, the cells were analyzed
by FACS and only clones with a single fluorescence signal
(mVenus or TagRFP positive), indicating unique copy inte-
gration, were chosen for future experiments.
The HEK 293T reporter cell line (AAVS1 TLR/+) (18) was
cultivated in the same conditions as the Neuro-2a cell line.
rAAV production and transduction
The rAAV were produced as previously described (19).
In brief, HEK 293T cells were grown in triple flasks for
24 h (DMEM, 10% fetal bovine serum) before transfec-
tion with AAV plasmids. The transgene plasmids and the
helper plasmid (pDP2rs, kindly provided by Ju¨rgen Klein-
schmidt, DKFZHeidelberg) were subsequently transfected
into the HEK 293T cells using Polyethylenimine (Sigma–
Aldrich PEI, Polysciences). After 72 h, the viruses were pu-
rified from benzonase-treated cell crude lysates overusing
an iodixanol density gradient (Optiprep, Sigma–Aldrich).
AAV titers were determined by real-time polymerase chain
reaction (PCR) on vector genomes using the SYBR Green
Master Mix (Roche).
For transduction using AAVs, the reporter cells were cul-
tivated in the same conditions as in the transfection exper-
iment with the following modifications: On the transduc-
tion day, cells were given 200 l fresh complete DMEM
medium and incubated overnight with 106 vg/cell. The next
day, fresh medium was added and 5 days post-transduction
the cells were directly analyzed by FACS.
Transfection
X-tremGENE HP DNA transfection reagent (#06 366 244
001, Roche) was used following the provider indications.
Briefly, 24 h before transfection 5 × 105 cells per well were
seeded in a 48-well plate. On the transfection day, cells were
given 300 l fresh complete DMEMmedium and the trans-
fection complex was prepared as follows: 0.03 g gRNA,
0.075 g of the different Cas9 variants expressing plasmids,
0.075 g of the donor plasmid carrying a complete Venus
cDNA (+ 0.4 and 1.5 kb as 5′ and 3′ homology arms, respec-
tively) without promotor for traffic light reporter experi-
ments, and completed up to one total of 0.3g ofDNAwith
pSK45 plasmid per well. All experiments were done in trip-
licate. Twenty four hours post-transfection, fresh medium
was added to the cells and 48 h post transfection the cells
were directly analyzed by FACS or lysed for DNA isolation.
FACS
Forty eight hours after the transfection, the cells were
trypsinized and resuspended in a single cell suspension in
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saline (PBS). A total of 104 cells were counted using the
FACSAria II and the number of cells with mVenus or
TagRFP positive signal were expressed as a percentage of
the total counted population. Cells transfected with Sp-
Cas9 plus gRNA were used as positive control and with-
out gRNA as negative control. The data were analyzed us-
ing the BD FACSDiva Software (Version 6.1.3, BD Bio-
sciences).
T7 Endonuclease I assay and RFLP analysis
The following primers pairs were used to amplify the
targeted loci: Fus, FUS-Fw (5′-CTATGGAGATGATC
GACGTG-3′) and FUS-Rv (5′-TGGTTACAATTAGGGT
AGTCTG-3′); Rosa26, Rosa26-Fw (5′-ACCTTTCTGG
GAGTTCTCTGCTGCC-3′) andRosa26-Rv (5′-TTCCCG
ACAAAACCGAAAATCTGTG-3′); Rab38, Rab38-Fw
(5′- GGCCTCCAGGATGCAGACACC-3′) and Rab38-
Rv (5′-CCAGCAATGTCCCAGAGCTGC-3′). In all cases
the amplicons were quantified on 2100 Bioanalyzer system
(Agilent Technologies). The T7 Endonuclease assay, as de-
scribed previously by Reynon et al. (20), was used to study
the gRNA-Fus and gRNA-Rosa26#1 activity. The Restric-
tion fragment length polymorphism (RFLP) analysis was
performed on the experiments with gRNA-Rosa26#3 and
gRNA-Rab38#2.
Plasmids
The same expression plasmid backbone published by
Brandl et al. (21) was used to express the gRNA,
SpCas9 and its variants. For rAAV experiments,
the plasmid LITE1.0 pAAV hSyn CRY2PHR-NLS-
VP64 2A GFP WPRE bGHpA (a gift from Feng Zhang,
Addgene plasmid # 48253) (22)) was used to construct
the different rAAV plasmids. A CBh promoter was used
to drive the expression of the split SpCas9 in the rAAV
vectors (23). All plasmid and gRNAs sequences used in
this study can be found in the supplementary information.
RESULTS
Design of Intein-mediated split SpCas9
Inteins can be easily explained as protein introns: They ex-
cise themselves out of a sequence and join the remaining
flanking regions (exteins) with a peptide bond without leav-
ing a scar (24). The coding regions of the catalytic sub-
unit of DNA polymerase III DnaE from the cyanobacteria
Nostoc punctiforme (Npu) are located in two genes, dnaE-n
and dnaE-c. The dnaE-n encoded protein consists of an N-
terminalDnaE fragment plus theN-intein, while dnaE-c en-
codes a protein that consists of the C-terminal DnaE frag-
ment preceded by a C-Intein entity. N-intein and C-Intein
recognize each other, splice themselves out and simultane-
ously ligate the flankingN- andC-terminal exteins resulting
in the recovery of the full-length DnaE (24).
We use this naturally occurring phenomenon by exchang-
ing the extein regions with the respective halves of SpCas9
(Figure 1a). The split-sites of SpCas9 were carefully chosen
between Glu573 and Cys574 for the first version (v1) or be-
tween Lys637 and Thr638 for the second version (v2), since
the N-terminal amino acid of the C-Cas9 in the C-Intein C-
Cas9 fusion should be Cys, Ser or Thr to ensure high splic-
ing efficiency (7,25) (Figure 1a).Moreover, particular atten-
tion was given such that the split-sites were surface-exposed
due to the sterical need for protein splicing (26).
The split–intein–Cas9 systems were created by fusing
the N- or C-terminal halves of SpCas9 to the correspond-
ing intein halves: v1 uses SpCas91-573 and SpCas9574-1368
as split–Cas9 moieties, resulting in two fusion constructs
called N-Cas9 N-Intein v1 and C-Intein C-Cas9 v1; v2
uses SpCas91-637 and SpCas9638-1368 as split–Cas9 moi-
eties, resulting in two fusion constructs called N-Cas9 N-
Intein v2 and C-Intein C-Cas9 v2 (Figure 1b).
Intein-mediated SpCas9 is as active as wild-type SpCas9 in
surrogate reporter systems
To test if the intein-reconstituted split Cas9 is active, we
used a Neuro-2a cell line carrying a single copy integrated
surrogate traffic light reporter (TLR). This reporter enables
the distinction between the twomajor repair pathways after
a double-strand break, mediated by the repair machinery
of the cell. This is (i) the error-prone non-homologous end-
joining (NHEJ) and (ii) the high-fidelity homology-directed
repair (HDR) (Figure 1c). NHEJ causes indels in the re-
porter region that will put TagRFP in frame in one third
of the total events, allowing its expression and detection
(red fluorescence); whereas HDR results in the expression
of the repaired mVenus (green fluorescence) (Figure 1c).
After 48 h of transient transfection with both variants of
the split–intein system (N-Cas9 N-Intein and C-Intein C-
Cas9 for v1 and v2) and an U6 expressed gRNA (Figure
2a), the resulting number of fluorescent cells, correspond-
ing to the sum of events from non-homologous end join-
ing (NHEJ) and homology directed repair (HDR), matches
the SpCas9 wild-type values, using a full-length SpCas9 and
gRNA (Figure 2a and b). In contrast to that, no fluores-
cence signal was detected in the negative controls in which
SpCas9 was expressed without gRNA (Figure 2b) or when
single intein-halves of SpCas9 alone were co-expressed with
the gRNA (Figure 2b).
Targeting efficiency of endogenous genes with intein-
mediated split–Cas9 system is comparable to wild-type Sp-
Cas9
In subsequent experiments, we validated our Intein-Cas9
system in several endogenous loci (Fus, Rosa26 and Rab38)
in Neuro-2a cells. The first gene chosen was Fus (fused in
sarcoma) because of its importance as a model for amy-
otrophic lateral sclerosis (27). The DNA of the entire cell
population was isolated 48 h after the transient transfec-
tion. The region containing the CRISPR/Cas9 target site
was PCR-amplified and the T7 endonuclease I assay was
performed. Indels will form mismatched duplexes after the
denaturing and reannealing step. T7 endonuclease I cleaves
these mismatched regions and the existence of indels was
revealed by the presence of digested PCR products (Figure
2c). As expected, only samples from cells exposed to the Sp-
Cas9, or to both moieties, presented the predicted digestion
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Figure 1. Using split-inteins for split–Cas9 reconstitution. (A) Upon split-intein reconstitution, the split-intein moieties splice themselves out and ligate
the flanking N- and C-terminal SpCas9 halves (exteins) resulting in the recovery of active full-length SpCas9. (B) Split-SpCas9 version 1: DnaE N-intein
(orange) is fused to the C-terminus of SpCas91-573(N-Cas9, red), whereas DnaE C-intein (green) is fused to N-terminus of SpCas9574-1368 (C-Cas9, blue).
Split-SpCas9 version 2: DnaE N-intein is fused to the C-terminus of SpCas91-637, whereas DnaE C-intein is fused to N-terminus of SpCas9638-1368. (C) To
measure nuclease activity, and to distinguish between HDR andNHEJ events, a traffic light reporter system was used. NHEJ events introduced by SpCas9,
will often create indels that lead to frameshift mutations, resulting in the expression of TagRFP. HDR events will result in the repair of the truncated Venus
by the repair template given (donor DNA; left homology arm: 0.4 kb, right homology arm: 1.4 kb) and the removal of the stop codon in the center of Venus
leading to the expression of full-length Venus. Translated regions are denoted as lines under the schematic DNA with translation start site and stop codon.
The box inset shows a detail of the target sequence recognized by the gRNAs crTLR#1 and crTLR#3. CAG: synthetic mammalian promoter CAG; bGH:
bovine growth hormone polyadenylation site.
and 22.7%, respectively), while in the negative controls none
were detected (Figure 2c and g).
To validate the results obtained targeting the Fus gene,
two other gene loci were targeted. We targeted Rosa26 as
a second genomic locus with two different gRNAs (Figure
2d and e). Rosa26 is widely used as a safe locus in mouse
to knock in foreign DNA (28). As in the previous exper-
iment, the region containing the predicted target sequence
was amplified by PCR. The presence of indels when gRNA-
Rosa26#1 was used was revealed by the T7 endonuclease I
assay, and the existence of anXbaI site on the binding site of
gRNA-Rosa26#3 permitted us to analyze the existence of
indels by RFLP. When gRNA-Rosa26#1 was used, the ex-
pected digested products were only detected when SpCas9
or the two SpCas9 moieties were added (64.0 and 48.1%, re-
spectively) (Figure 2d, g). These data were confirmed using
a second gRNA, gRNA-Rosa26#3. In this case, the indels
will disrupt the XbaI site, resulting in XbaI resistant mu-
tant DNA fragments (Figure 2e). Again we observed that
the nuclease activity observed with SpCas9 intein-split ver-
sion (42.9%) was comparable to wild-type SpCas9 (50.2%)
(Figure 2e and g).
As a third locus, we targeted the Rab38 locus (Figure 2f).
This locus was used by us before as a proof of principle ge-
nomic region to test nuclease activity of ZFN, TALEN and
CRISPR/Cas9 (21,29). The region containing the target se-
quence of the gRNA-Rab38#2 was PCR-amplified and an-
alyzed by RFLP. The presence of indels was revealed by loss
of XcmI site, whereas the wild-typeDNAwas digested (Fig-
ure 2f). The undigested product was only detectable when
both split SpCas9 moieties (24.9%) or SpCas9 (22.7%) were
used (Figure 2f and g).
The intein-mediated split–Cas9 system can be efficiently de-
livered via rAAV
The goal of developing an intein-mediated split–Cas9
system was to permit the efficient delivery via rAAVs.
To demonstrate this, two recombinant AAV were
produced, each carrying a split-half of the system
(pAAV crTLR#1 Nv1 and pAAV crTLR#1 Cv1) (Figure
3a). A human cell line, AAVS1 TLR/+ (18), and a mouse
cell line, Neuro-2a TLR, were used to validate our system.
When the AAVS1 TLR/+ cell line was transduced with both
rAAVs, the relative nuclease activity was at two orders
of magnitude higher than the negative control or when
only one rAAV was used (Figure 3b). In the case of the
Neuro-2a TLR, a similar result was observed. The relative
nuclease activity was one order of magnitude higher than
the negative control and the single rAAV experiments (Fig-
ure 3c). In both cases, the actual activity observed was even
higher because, with this reporter system, only one-third
of the theoretical total nuclease activity is detected. These
results demonstrate that the delivery of a complete full
CRISPR/Cas9 system is possible using two rAAV without
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Figure 2. Testing split–Cas9 efficiency in Neuro-2a TLR cell lines. (A) Overview of the WT and split–Cas9 expression plasmids used (Cas9, N-Cas9 N-
Intein v1, C-Intein C-Cas9 v1, N-Cas9 N-Intein v2, C-Intein C-Cas9 v2, gRNA crTLR#1/#2). To ensure a high expression; a strong synthetic mam-
malian promoter (CAG, green) and a bovine growth hormone (bGH, red) polyadenylation site was used. Cas9 cDNA is shown in orange, N-intein in
dark brown and C-Intein in light brown. NLS (dark red): Nuclear localization signal. FLAG and HA tag are shown in light and dark grey respectively.
For gRNA expression (turquoise), U6 promoter was chosen (dark green). (B) Results after FACS: only transfection with both N- and C-terminal parts of
the split–intein–Cas9 system for version 1 (v1) and version 2 (v2) resulted in nuclease activity similar to wild-type SpCas9, represented in HDR or NHEJ
events; transfection with only one moiety did not show any observable HDR or NHEJ events. Shown are means ± SD of three independent experiments.
(C) The split-intein-Cas9 system v1 was used to target the fused in sarcoma (Fus) gene’s second last exon. The respective segment was PCR amplified
with the annotated primers for further analysis. T7 endonuclease I assay was performed after PCR on the samples to investigate the occurrence of NHEJ
events. After the assay, the samples were analyzed with a Bioanalyzer. The appearance of a second band indicates the presence of indels resulting from
NHEJ events. (D) Targeting of Rosa26 locus with the gRNA Rosa26#1. Only indels were detected when SpCas9 wild-type or both SpCas9 moieties were
transfected. (E) Targeting of Rosa26 locus with the gRNA Rosa26#3. Indels were detected by RFLP analysis. The XbaI resistant product could be only
observed when SpCas9 wild-type or both SpCas9moieties were transfected. (F) Targeting of Rab38 locus with the gRNARab38#2. Indels were detected by
RFLP analysis. The XcmI resistant product could be only observed when SpCas9 wild-type or both SpCas9 moieties were transfected. (G) Quantification
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Figure 3. Demonstration that the split-intein split-SpCas9 system can be delivered by rAAV. (A) Overview of the split–Cas9 rAAV constructs
(pAAV crTLR#1 Nv1, pAAV crTLR#1 Cv1). To ensure a high expression; a strong synthetic mammalian promoter (CBh, green) and a bovine growth
hormone (bGH, red) polyadenylation site was used. Split Cas9 cDNA is shown in orange, N-intein in dark brown and C-Intein in light brown. NLS (dark
red): Nuclear localization signal. FLAG and HA tag are shown in light and dark grey, respectively. For gRNA expression (turquoise), U6 promoter was
chosen (dark green). The inverted terminal repeats (ITR) are shown in light blue and light green. (B and C) Only nuclease activity was detectable when
the two rAAV carrying the two moieties were added to the AAVS1 TLR/+ (b) or to the Neuro-2a TLR cells (c). In the experiments with only one of the
moieties, the nuclease activity was indistinguishable from the negative control. Shown are means ± SD of three independent experiments.
An intein-mediated Cas9 D10A nickase is functional and
comparable to SpCas9 D10A
SpCas9 D10A nickases have been reported to significantly
reduce genomic off-targets in vitro, which is of great impor-
tance for the usage of CRISPR-Cas9 in gene therapy (30).
Therefore, we designed an intein-mediated split–Cas9 sys-
tem (Figure 4a) to compare its efficiency in HDR-NHEJ-
ratio to the unmodified SpCas9D10Anickase using the traf-
fic light reporter cell line and two gRNAs (crTLR#1 and
crTLR#3) (Figure 1c) and to the SpCas9 wild-type. Inter-
estingly, the nickases showed higher preference for HDR
than the wild-type SpCas9 (Figure 4c) with reduced NHEJ
values. The split-nickase also shares the same ratio HDR
versusNHEJ than SpCas9D10A nickase, but with a slightly
overall decreased activity compared to wild-type. Its HDR
efficiency was nevertheless as efficient as wild-type SpCas9
but with greatly reduced NHEJ (Figure 4c).
The donor DNA can be accommodated on the same plasmid
encoding the split–CRISPR/Cas9 system
Many inherited diseases are monogenetic, originating from
a point mutation in the corresponding gene, which there-
fore can be, in theory, corrected if a template region is pro-
vided after a DSB event. There is about 0.9 kb left on
the dual-vector system before reaching the 5 kb, to inte-
grate additional sequences. Thus, we included a donor se-
quence into one of the split–Cas9 plasmids (Figure 4b),
and tested their efficiency using our TLR reporter sys-
tem, in comparison to adding the donor as an indepen-
dent plasmid. In addition, two versions of the rAAV-vector-
encoded repair template were created: the first version
contained the donor region, while, in the second version,
the donor region was additionally flanked by CRISPR
recognition sites (pAAV crTLR#1 CRISPR-Donor Nv1,
pAAV crTLR#1 Donor Nv1, Figure 4b). When this sys-
temwas tested by plasmid transfection, theHDRvalues ob-
served with the non-flanked donor were comparable to the
wild-type and split SpCas9 variants in the presence of an
extra donor plasmid (Figure 4c). In the case of the flanked
donor, the nuclease activity was lower. This could be prob-
ably caused by DNA instability after being cut by SpCas9
(Figure 4c). These results can be useful in designing a vec-
tor system for genome engineering with a lower number of
plasmids, making the transfection of all of them easier.
DISCUSSION
CRISPR/Cas9 has been widely adopted as a powerful tool
for gene targeting in several different species and, more re-
cently, for ex vivo gene therapy treatment. The B2M and
CCR5 receptors in human hematopoietic stem and progen-
itor cells were successfully knocked out, as recently shown
by Mandal et al. (31). However, in spite of its immense po-
tential, use of the CRISPR/Cas9 system for in vivo gene
therapy is impeded by the difficulties in ensuring efficient
delivery. Recently, successful delivery of SpCas9 by rAAVs
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Figure 4. Plasmid transfection experiment for comparison of SpCas9 wild-type and nickase with its respective split versions, and of donor DNA
as separate plasmid or accommodated directly on the AAV plasmid. (A) Overview of the split–Cas9 plasmids used to express SpCas9, Sp-
Cas9D10A and its split version (Cas9, Cas9D10A, N-Cas9 N-Intein v1, C-Intein C-Cas9 v1, gRNA crTLR#1/#2. (B) rAAV plasmids used: without
donor sequence (pAAV crTLR#1 Nv1), carrying the donor DNA flanked by CRISPR sites (pAAV crTLR#1 CRISPR-Donor Nv1) or not flanked
(pAAV crTLR#1 Donor Nv1), C-Cas9 expression plasmid (pAAV crTLR#1 Cv1). CBh promoter is shown in green, bovine growth hormone (bGH,
red). Split Cas9 cDNA is shown in orange, N-intein in dark brown and C-Intein in light brown. NLS (dark red): Nuclear localization signal. FLAG and
HA tag are shown in light and dark grey, respectively. For gRNA expression (turquoise), U6 promoter was chosen (dark green). The inverted terminal
repeats (ITR) are shown in light blue and light green. Donor DNA sequence (Donor, dark green) (C) The double nicking strategy, SpCas9D10A in combi-
nation with two gRNAs, showed a preference for HDR compared to wild-type. This effect was also observed with split-SpCas9D10A but with decreased
activity.With the different DNAdonor strategies no differences were observed, but with donorDNAflanked by CRISPR sites reducedHDRwas observed.
Shown are means ± SD of three independent experiments.
strict limitations in the Cas9 expression promoter length. If
longer promoters are needed to drive the Cas9 expression to
a specific cell population, an alternative strategy is needed.
Thus, there exists a pressing need to develop alternative sys-
tems to decrease the size to be carried.
Here, we showed that SpCas9 can be functionally
split and rapidly reconstituted out of two inactive split-
fragments using Npu split-inteins, without impairing its en-
donuclease efficiency. We also show that rAAV vectors are
an amenable delivery system for split SpCas9, offering new
possibilities for gene therapy. Splitting proteins is not always
trivial because split proteins tend to form aggregates when
their hydrophobic core regions are exposed to solvent when
split (33). In addition, folding order in some cases is cru-
cial when protein subdomains need to fold in a cooperative
manner (34). In contrast, the bilobed spatial tertiary struc-
ture of SpCas9, and its hydrophilic and positively charged
groove between the two lobes in which the gRNA/DNA
partially resides, appears ideal for splitting (8).
In this work, we prove the feasibility of a split–Cas9 sys-
tem. Using this strategy, it is possible to circumvent the
packaging limit of rAAVs for gene therapy applications, by
generating two different rAAV populations encoding each
of the respective halves of Cas9 fused to the corresponding
inteins (7). Furthermore, this strategy could be also used
for intersectional mutagenesis to improve specificity by us-
ing different promoters. Only cells that co-express bothmoi-
eties lead to the reconstitution of an active SpCas9, leading
to a predicted improved accuracy in cell targeting in in vivo
applications. Another improvement of the system would be
the replacement of the naturally occurring split-inteins of
Npu with the artificial VMA split-intein from S. cerevisiae
(Sce) (35). In contrast to the Npu DnaE intein system, the
Sce VMA split-intein pair is artificially split and shows no
affinity between its halves. This allows conditional in vivo
reconstitution of the artificial Sce split-intein and thus the
reconstitution of full-length Cas9 by protein pairs that in-
teract with each other upon certain chemical or physical
triggers, e.g. FKBP/FRB for ligand-induced dimerization
(35,36) or Cry2/Cib1 and PhyB/PIF6 for a light-induced
dimerization (36).
We also showed that converting the intein-nuclease sys-
tem into a nickase system was analogously possible. Of
note, we observed that, with the double nicking strategy,
the HDR is preferred over NHEJ as a DNA repair mech-
anism. Increasing HDR makes the double nicking system
a very attractive option for gene repair-based therapeutic
strategies. In addition, we demonstrated that it is not nec-
essary to deliver the repair template as an extra plasmid,
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the same dual rAAV vector system. Recently, a similar ap-
proach was published, where a plasmid, carrying as donor
DNA the entire CRISPR/Cas9 system sequence flanked by
homology arms, was correctly integrated in a pre-defined
site (37). However, Gantz et al. focused on the generation
of germline mutations in drosophila melanogaster. In this re-
port, we showed that also gene repair is efficiently possible
in a mouse cell line. This emphasizes its potential utility for
future gene therapy strategy design. The same principle can
be also applied for the nuclease-dead SpCas9 (dCas9) fused
to various transcription activators/repressors or epigenetic
modulators (38,39) as well as for RNA targeting (40), and
developing new genetic circuits using logic gates (41,42).
During the review process of this manuscript, two inde-
pendent groups published data showing that it is possible
to split SpCas9 by using different strategies (43,44). Zetsche
et al. (43), using a rapamycin-inducible split–Cas9 system,
also described that one of the most active split-sites was
the same we identified in our split-intein split–Cas9 sys-
tem (Glu573–Cys574). Nevertheless, Zetsche used a lentivi-
ral system that stably integrated the rapamycin-inducible
expression cassettes into the genome. Afterwards, they se-
lected cells carrying these constructs and achieved the max-
imum efficiency (40%) after 4–6 weeks of rapamycin incu-
bation (43). Most recently, Wright et al. (44) also showed
that split–Cas9 is functional in in vitro assays. This was
shown by in vitro cleavage of dsDNA via the pre-assembled
recombinant produced halves of split–Cas9 when gRNAs
were present. In spite of this, upon nucleofection of the pre-
assembled complex into cells, no notable nuclease activity
was observed (0.6%). In contrast, wild-type SpCas9 showed
22% genomic modifications.
In summary, we were able to prove that it is possible to
split SpCas9 and its nickase derivatives using natural split–
inteins without affecting its endonuclease activity. Further-
more, we demonstrated for the first time that the split Sp-
Cas9 can be efficiently delivered using a dual rAAV vec-
tor system. Moreover, we showed that the delivery of a re-
pair template on the dual-vector system is possible. This ap-
proach allows the exploitation of the CRISPR/Cas system
potential for gene therapy, avoiding the existing rAAVpack-
aging size problem.
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